Tuberculosis: Current state of knowledge: An epilogue

Respirology

Volumn 18, Issue 7, 2013, Pages 1047-1055

  Leung, Chi Chiu ^a   Lange, Christoph ^b   Zhang, Ying ^c  

^a DEPARTMENT OF HEALTH   (Hong Kong)

^b German Center for Infection Research (DZIF) Clinical Tuberculosis Unit   (Germany)

^c JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

diagnosis; latent infection; treatment; tuberculosis; vaccine

Indexed keywords

6,7 DIHYDRO 2 NITRO 6 (4 TRIFLUOROMETHOXYBENZYLOXY) 5H IMIDAZO[2,1 B][1,3]OXAZINE; AMIKACIN; AMINOGLYCOSIDE ANTIBIOTIC AGENT; ANTIRETROVIRUS AGENT; BCG VACCINE; BEDAQUILINE; BIOLOGICAL PRODUCT; CAPREOMYCIN; DELAMANID; GATIFLOXACIN; ISONIAZID; KANAMYCIN; LINEZOLID; MOXIFLOXACIN; PYRAZINAMIDE; QUINOLONE DERIVATIVE; RIFAMPICIN; RIFAMYCIN DERIVATIVE; RIFAPENTINE; STREPTOMYCIN;

AIRBORNE INFECTION; ANTIBIOTIC SENSITIVITY; BACTERIAL GROWTH; BACTERIAL STRAIN; BCG VACCINATION; COUGHING; CROSS REACTION; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; EXTENSIVELY DRUG RESISTANT TUBERCULOSIS; FEVER; HEART ARRHYTHMIA; HUMAN; IMMUNITY; INCIDENCE; INFECTION CONTROL; INTERFERON GAMMA RELEASE ASSAY; KNOWLEDGE; LATENT TUBERCULOSIS; LIVER TOXICITY; MINIMUM INHIBITORY CONCENTRATION; MORTALITY; MULTIDRUG RESISTANT TUBERCULOSIS; MYCOBACTERIUM TUBERCULOSIS; NIGHT SWEAT; PREDICTIVE VALUE; PRIORITY JOURNAL; QT PROLONGATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REAL TIME POLYMERASE CHAIN REACTION; REVIEW; RHEUMATOID ARTHRITIS; RISK FACTOR; SCREENING TEST; SENSITIVITY AND SPECIFICITY; SHORT COURSE THERAPY; SPUTUM CULTURE; SPUTUM CYTODIAGNOSIS; SPUTUM SMEAR; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; SYSTEMS BIOLOGY; THORAX RADIOGRAPHY; TUBERCULOSIS; WEIGHT REDUCTION;

DIAGNOSIS; LATENT INFECTION; TREATMENT; TUBERCULOSIS; VACCINE;

ANTITUBERCULAR AGENTS; BCG VACCINE; DRUG RESISTANCE, MULTIPLE, BACTERIAL; HUMANS; LATENT TUBERCULOSIS; MYCOBACTERIUM TUBERCULOSIS; SYSTEMS BIOLOGY; TUBERCULOSIS VACCINES; TUBERCULOSIS, PULMONARY;

EID: 84884828537     PISSN: 13237799     EISSN: 14401843     Source Type: Journal    
DOI: 10.1111/resp.12156     Document Type: Review

References (110)

1. Chiang CY, Van Weezenbeek C, Mori T, et al. Challenges to the global control of tuberculosis. Respirology 2013; 18: 596-604.
2. Dheda K, Ruhwald M, Theron G, et al. Point-of-care diagnosis of tuberculosis: past, present and future. Respirology 2013; 18: 217-232.
3. Chang KC, Yew WW,. Management of difficult multidrug-resistant tuberculosis and extensively drug-resistant tuberculosis: update 2012. Respirology 2013; 18: 8-21.
4. Chee CB, Sester M, Zhang W, et al. Diagnosis and treatment of latent infection with Mycobacterium tuberculosis. Respirology 2013; 18: 205-216.
5. Lee SS, Meintjes G, Kamarulzaman A, et al. Management of tuberculosis and latent tuberculosis infection in HIV-infected persons. Respirology 2013; 18: 912-922.
6. To KW, Reino JJ, Yoo DH, et al. Tumor necrosis factor antagonist and tuberculosis in patients with rheumatoid arthritis: an Asian perspective. Respirology 2013; 18: 765-773.
7. Wang CC, Zhu B, Fan X, et al. Systems approach to tuberculosis vaccine development. Respirology 2013; 18: 412-420.
8. Styblo K,. The epidemiology and control of tuberculosis in developed countries. Ther. Umsch. 1973; 30: 199-206.
9. Styblo K, Bumgarner R,. Tuberculosis can be controlled with existing technologies: evidence. Tuberc. Surveill. Res. Unit Prog. Rep. 1991; 2: 60-72.
10. Forty-Fourth World Health Assembly. Tuberculosis control programme. [Accessed 9 Jun 2013.] Available from URL: http://www.who.int/tb/publications/ tbresolution-wha44-8-1991.pdf
11. Grzybowski S, Enarson D,. [Results in pulmonary tuberculosis patients under various treatment program conditions]. Bull. Int. Union Tuberc. 1978; 53: 70-75. [Article in French)].
12. World Health Organization. Global tuberculosis report 2012. World Health Organization Document 2012; WHO/HTM/TB/2012.6: 1-272.
13. Zhao Y, Xu S, Wang L, et al. National survey of drug-resistant tuberculosis in China. N. Engl. J. Med. 2012; 366: 2161-2170.
14. Udwadia ZF, Amale RA, Ajbani KK, et al. Totally drug-resistant tuberculosis in India. Clin. Infect. Dis. 2012; 54: 579-581.
15. Cain KP, McCarthy KD, Heilig CM, et al. An algorithm for tuberculosis screening and diagnosis in people with HIV. N. Engl. J. Med. 2010; 362: 707-716.
16. Rangaka MX, Wilkinson RJ, Glynn JR, et al. Effect of antiretroviral therapy on the diagnostic accuracy of symptom screening for intensified tuberculosis case finding in a South African HIV clinic. Clin. Infect. Dis. 2012; 55: 1698-1706.
17. Meijer J, Barnett GD, Kubik A, et al. Identification of sources of infection. Bull. Int. Union Tuberc. 1971; 45: 5-50.
18. Toman K,. Mass radiography in tuberculosis control. WHO Chron. 1976; 30: 51-57.
19. Ho TT, Wong KH, Lee SS,. Low yield of chest radiography in screening for active pulmonary tuberculosis in HIV-infected patients in Hong Kong. Int. J. STD AIDS 1999; 10: 409-412.
20. Leung CC,. Reexamining the role of radiography in tuberculosis case finding. Int. J. Tuberc. Lung Dis. 2011; 15: 1279.
21. China Tuberculosis Control Collaboration. Results of directly observed short-course chemotherapy in 112 842 Chinese patients with smear-positive tuberculosis. Lancet 1996; 347: 358-362.
22. Hanifa Y, Fielding KL, Charalambous S, et al. Tuberculosis among adults starting antiretroviral therapy in South Africa: the need for routine case finding. Int. J. Tuberc. Lung Dis. 2012; 16: 1252-1259.
23. Van't Hoog AH, Meme HK, van Deutekom H, et al. High sensitivity of chest radiograph reading by clinical officers in a tuberculosis prevalence survey. Int. J. Tuberc. Lung Dis. 2011; 15: 1308-1314.
24. Perkins MD, Cunningham J,. Facing the crisis: improving the diagnosis of tuberculosis in the HIV era. J. Infect. Dis. 2007; 196 (Suppl. 1): S15-27.
25. Aliyu G, El-Kamary SS, Abimiku A, et al. Prevalence of non-tuberculous mycobacterial infections among tuberculosis suspects in Nigeria. PLoS One 2013; 8: e63170.
26. World Health Organization Policy Statement 2011. Fluorescent Light-Emitting Diode (LED) Microscopy for Diagnosis of Tuberculosis. WHO, Geneva, Switzerland, 2011.
27. Ramsay A, Yassin MA, Cambanis A, et al. Front-loading sputum microscopy services: an opportunity to optimise smear-based case detection of tuberculosis in high prevalence countries. J. Trop. Med. 2009; 2009: 398767.
28. Minion J, Leung E, Menzies D, et al. Microscopic-observation drug susceptibility and thin layer agar assays for the detection of drug resistant tuberculosis: a systematic review and metaanalysis. Lancet Infect. Dis. 2010; 10: 688-698.
29. Farnia P, Masjedi MR, Mohammadi F, et al. Colorimetric detection of multidrug-resistant or extensively drug-resistant tuberculosis by use of malachite green indicator dye. J. Clin. Microbiol. 2008; 46: 796-799.
30. Gupta M, Singh NP, Kaur IR,. Evaluation of nitrate reductase assay for direct detection of drug resistance in Mycobacterium tuberculosis: rapid and inexpensive method for low-resource settings. Indian J. Med. Microbiol. 2010; 28: 363-365.
31. Zhang Y, Yew WW,. Mechanisms of drug resistance in Mycobacterium tuberculosis, state of the art. Int. J. Tuberc. Lung Dis. 2009; 13: 1320-1330.
32. World Health Organisation Policy Statement 2011. Automated real-time nucleic acid amplification technology for rapid and simultaneous detection of tuberculosis and rifampicin resistance: Xpert MTB/RIF System. [Accessed 9 Jun 2013.] Available from URL: http://whqlibdoc.who.int/publications/2011/ 9789241501545-eng.pdf
33. Chang K, Lu W, Wang J, et al. Rapid and effective diagnosis of tuberculosis and rifampicin resistance with Xpert MTB/RIF assay: a meta-analysis. J. Infect. 2012; 64: 580-588.
34. Lawn SD, Brooks SV, Kranzer K, et al. Screening for HIV associated tuberculosis and rifampicin resistance before antiretroviral therapy using the Xpert MTB/RIF assay: a prospective study. PLoS Med. 2011; 8: e1001067.
35. Kim SY, Kim H, Kim SY, et al. The Xpert® MTB/RIF assay evaluation in South Korea, a country with an intermediate tuberculosis burden. Int. J. Tuberc. Lung Dis. 2012; 16: 1471-1476.
36. Minion J, Leung E, Talbot E, et al. Diagnosing tuberculosis with urine lipoarabinomannan: systematic review and metaanalysis. Eur. Respir. J. 2011; 38: 1398-1405.
37. Lawn SD, Kerkhoff AD, Vogt M, et al. Clinical significance of lipoarabinomannan (LAM) detection in urine using a low-cost point-of-care diagnostic assay for HIV-associated tuberculosis. AIDS 2012; 26: 1635-1643.
38. Fox W, Ellard GA, Mitchison DA,. Studies on the treatment of tuberculosis undertaken by the British Medical Research Council tuberculosis units, 1946-1986, with relevant subsequent publications. Int. J. Tuberc. Lung Dis. 1999; 3 (10 Suppl. 2): S231-279.
39. Hong Kong Chest Service/British Medical Research Council. Controlled trial of 2, 4 and 6 months of pyrazinamide in 6-month three-times-weekly regimens for smear-positive pulmonary tuberculosis, including an assessment of a combined preparation of isoniazid, rifampin and pyrazinamide. Results at 30 months. Am. Rev. Respir. Dis. 1991; 143: 700-706.
40. Singapore Tuberculosis Service/British Medical Research Council. Five year follow up of a clinical trial of three 6-month regimens of chemotherapy given intermittently in the continuation phase in the treatment of pulmonary tuberculosis. Am. Rev. Respir. Dis. 1988; 137: 1147-1150.
41. Yee D, Valiquette C, Pelletier M, et al. Incidence of serious side effects from first-line antituberculosis drugs among patients treated for active tuberculosis. Am. J. Respir. Crit. Care Med. 2003; 167: 1472-1477.
42. American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America. Treatment of tuberculosis. Am. J. Respir. Crit. Care Med. 2003; 167: 603-662.
43. Chang KC, Leung CC, Yew WW, et al. Dosing schedules of 6-month regimens and relapse for pulmonary tuberculosis. Am. J. Respir. Crit. Care Med. 2006; 174: 1153-1158.
44. Swaminathan S, Narendran G, Venkatesan P, et al. Efficacy of a 6-month versus 9-month intermittent treatment regimen in HIV-infected patients with tuberculosis: a randomized clinical trial. Am. J. Respir. Crit. Care Med. 2010; 181: 743-751.
45. Centers for Disease Control. Outbreak of multidrug-resistant tuberculosis-Texas, California, and Pennsylvania. JAMA 1990; 264: 173-174.
46. Mitchison DA,. Problems of drug resistance. Br. Med. Bull. 1954; 10: 115-124.
47. Mitchison DA,. Treatment of tuberculosis. The Mitchell Lecture 1979. J. R. Coll. Physicians Lond 1980; 14: 91-99.
48. Global Alliance for TB Drug Development. Scientific blueprint for tuberculosis drug development. Tuberculosis (Edinb.) 2001; 81 (Suppl. 1): 1-52.
49. Yew WW, Chan CK, Chau CH, et al. Outcomes of patients with multidrug-resistant pulmonary tuberculosis treated with ofloxacin/levofloxacin- containing regimens. Chest 2000; 117: 744-751.
50. Lee M, Lee J, Carroll MW, et al. Linezolid for treatment of chronic extensively drug-resistant tuberculosis. N. Engl. J. Med. 2012; 367: 1508-1518.
51. Global Alliance for TB Drug Development. Drug development pipeline of the Global Alliance for TB Drug Development. [Accessed 9 Jun 2013.] Available from URL: http://www.tballiance.org/downloads/mediakit/TBA-Pipeline-May-2013.pdf
52. Diacon AH, Donald PR, Pym A, et al. Randomized pilot trial of eight weeks of bedaquiline (TMC207) treatment for multidrug-resistant tuberculosis: long-term outcome, tolerability, and effect on emergence of drug resistance. Antimicrob. Agents Chemother. 2012; 56: 3271-3276.
53. Diacon AH, Dawson R, von Groote-Bidlingmaier F, et al. 14-day bactericidal activity of PA-824, bedaquiline, pyrazinamide, and moxifloxacin combinations: a randomised trial. Lancet 2012; 380: 986-993.
54. Gler MT, Skripconoka V, Sanchez-Garavito E, et al. Delamanid for multidrug-resistant pulmonary tuberculosis. N. Engl. J. Med. 2012; 366: 2151-2160.
55. Zhang Y, Yew WW, Barer M,. Targeting tuberculosis persisters for improved control. Antimicrob. Agents Chemother. 2012; 56: 2223-2230.
56. Sahota T, Della Pasqua O,. Feasibility of a fixed-dose regimen of pyrazinamide and its impact on systemic drug exposure and liver safety in patients with tuberculosis. Antimicrob. Agents Chemother. 2012; 56: 5442-5449.
57. Food and Drug Administration. News release on 31 Dec 2012. [Accessed 9 Jun 2013.] Available from URL: http://www.fda.gov/NewsEvents/Newsroom/ PressAnnouncements/ucm333695.htmFDA
58. Controlled Comparison of Two Moxifloxacin Containing Treatment Shortening Regimens in Pulmonary Tuberculosis (REMoxTB). [Accessed 9 Jun 2013.] Available from URL: http://www.clinicaltrials.gov/ct2/show/NCT00864383
59. Leung CC, Yew WW, Grosset J,. Harnessing the full sterilising activity of rifamycins. Int. J. Tuberc. Lung Dis. 2011; 15: 429-430.
60. Ängeby K, Juréen P, Kahlmeter G, et al. Challenging a dogma: antimicrobial susceptibility testing breakpoints for Mycobacterium tuberculosis. Bull. World Health Organ. 2012; 90: 693-698.
61. Ahuja SD, Ashkin D, Avendano M, et al. Multidrug resistant pulmonary tuberculosis treatment regimens and patient outcomes: an individual patient data meta-analysis of 9,153 patients. PLoS Med. 2012; 9: e1001300.
62. Van Deun A, Maug AK, Salim MA, et al. Short, highly effective, and inexpensive standardized treatment of multidrug-resistant tuberculosis. Am. J. Respir. Crit. Care Med. 2010; 182: 684-692.
63. Chang KC, Yew WW, Cheung SW, et al. Can intermittent dosing optimize prolonged linezolid treatment of difficult multidrug-resistant tuberculosis? Antimicrob. Agents Chemother. 2013; 57: 3445-3449.
64. Chang KC, Leung CC, Daley CL,. Linezolid for multidrug-resistant tuberculosis. Lancet Infect. Dis. 2012; 12: 502-503.
65. Butov DA, Efremenko YV, Prihoda ND, et al. Adjunct immune therapy of first-diagnosed TB, relapsed TB, treatment-failed TB, multidrug-resistant TB and TB/HIV. Immunotherapy 2012; 4: 687-695.
66. Blanc FX, Sok T, Laureillard D, et al. Earlier versus later start of antiretroviral therapy in HIV-infected adults with tuberculosis. N. Engl. J. Med. 2011; 365: 1471-1481.
67. Havlir DV, Kendall MA, Ive P, et al. Timing of antiretroviral therapy for HIV-1 infection and tuberculosis. N. Engl. J. Med. 2011; 365: 1482-1491.
68. Abdool Karim SS, Naidoo K, Grobler A, et al. Timing of antiretroviral therapy for HIV-1 infection and tuberculosis. N. Engl. J. Med. 2011; 365: 1492-1501.
69. Manosuthi W, Mankatitham W, Lueangniyomkul A, et al. Time to initiate antiretroviral therapy between 4 weeks and 12 weeks of tuberculosis treatment in HIV-infected patients: results from the TIME study. J. Acquir. Immune Defic. Syndr. 2012; 60: 377-383.
70. Török ME, Yen NT, Chau TT, et al. Timing of initiation of antiretroviral therapy in human immunodeficiency virus (HIV)-associated tuberculous meningitis. Clin. Infect. Dis. 2011; 52: 1374-1383.
71. Dye C, Scheele S, Dolin P, et al. Consensus statement. Global burden of tuberculosis: estimated incidence, prevalence, and mortality by country. WHO Global Surveillance and Monitoring Project. JAMA 1999; 282: 677-686.
72. Leung CC, Rieder HL, Lange C, et al. Treatment of latent infection with m. tuberculosis: update 2010. Eur. Respir. J. 2011; 37: 690-711.
73. Pai M, Zwerling A, Menzies D,. Systematic review: T-cell-based assays for the diagnosis of latent tuberculosis infection: an update. Ann. Intern. Med. 2008; 149: 177-184.
74. Rangaka MX, Wilkinson KA, Glynn JR, et al. Predictive value of interferon-γ release assays for incident active tuberculosis: a systematic review and meta-analysis. Lancet Infect. Dis. 2012; 12: 45-55.
75. Leung CC,. Tests for prediction of active tuberculosis. Lancet Infect. Dis. 2012; 12: 6-8.
76. Smieja M, Marchetti C, Cook D, et al. Isoniazid for preventing tuberculosis in non-HIV infected persons. Cochrane Database Syst. Rev. 1999; (1): CD001363. doi: 10.1002/14651858.CD001363
77. Akolo C, Adetifa I, Shepperd S, et al. Treatment of latent tuberculosis infection in HIV infected persons. Cochrane Database Syst. Rev. 2010; (1): CD000171. doi: 10.1002/14651858.CD000171.pub3
78. Samandari T, Agizew TB, Nyirenda S, et al. 6-month versus 36-month isoniazid preventive treatment for tuberculosis in adults with HIV infection in Botswana: a randomised, double-blind, placebo-controlled trial. Lancet 2011; 377: 1588-1598.
79. Martinson NA, Barnes GL, Moulton LH, et al. New regimens to prevent tuberculosis in adults with HIV infection. N. Engl. J. Med. 2011; 365: 11-20.
80. Madhi SA, Nachman S, Violari A, et al. Primary isoniazid prophylaxis against tuberculosis in HIV-exposed children. N. Engl. J. Med. 2011; 365: 21-31.
81. Hong Kong Chest Service/Tuberculosis Research Centre, Madras/British Medical Research Council. A double-blind placebo-controlled clinical trial of three antituberculosis chemoprophylaxis regimens in patients with silicosis in Hong Kong. Am. Rev. Respir. Dis. 1992; 145: 36-41.
82. Sterling TR, Villarino ME, Borisov AS, et al. Three months of rifapentine and isoniazid for latent tuberculosis infection. N. Engl. J. Med. 2011; 365: 2155-2166.
83. Holland DP, Sanders GD, Hamilton CD, et al. Strategies for treating latent multiple-drug resistant tuberculosis: a decision analysis. PLoS One 2012; 7: e30194.
84. Singh JA, Wells GA, Christensen R, et al. Adverse effects of biologics: a network meta-analysis and Cochrane overview. Cochrane Database Syst. Rev. 2011; (2): CD008794. doi: 10.1002/14651858.CD008794.pub2
85. Dixon WG, Hyrich KL, Watson KD, et al. Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register (BSRBR). Ann. Rheum. Dis. 2010; 69: 522-528.
86. Tubach F, Salmon D, Ravaud P, et al. Risk of tuberculosis is higher with anti-tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy: the three-year prospective French Research Axed on Tolerance of Biotherapies registry. Arthritis Rheum. 2009; 60: 1884-1894.
87. Jung YJ, Lyu J, Yoo B, et al. Combined use of a TST and the T-SPOT®.TB assay for latent tuberculosis infection diagnosis before anti-TNF-α treatment. Int. J. Tuberc. Lung Dis. 2012; 16: 1300-1306.
88. Smith MY, Attig B, McNamee L, et al. Tuberculosis screening in prescribers of anti-tumor necrosis factor therapy in the European Union. Int. J. Tuberc. Lung Dis. 2012; 16: 1168-1173.
89. Metcalfe JZ, Cattamanchi A, McCulloch CE, et al. Test variability of the QuantiFERON-TB gold in-tube assay in clinical practice. Am. J. Respir. Crit. Care Med. 2013; 187: 206-211.
90. Park JH, Seo GY, Lee JS, et al. Positive conversion of tuberculin skin test and performance of interferon release assay to detect hidden tuberculosis infection during anti-tumor necrosis factor agent trial. J. Rheumatol. 2009; 36: 2158-2163.
91. Lee SW, Oh DK, Lee SH, et al. Time interval to conversion of interferon-gamma release assay after exposure to tuberculosis. Eur. Respir. J. 2011; 37: 1447-1452.
92. Leung CC, Lam TH, Chan WM, et al. Lower risk of tuberculosis in obesity. Arch. Intern. Med. 2007; 167: 1297-1304.
93. Leung CC, Li T, Lam TH, et al. Smoking and tuberculosis among the elderly in Hong Kong. Am. J. Respir. Crit. Care Med. 2004; 170: 1027-1033.
94. Leung CC, Lam TH, Chan WM, et al. Diabetic control and risk of tuberculosis: a cohort study. Am. J. Epidemiol. 2008; 167: 1486-1494.
95. Suthar AB, Lawn SD, del Amo J, et al. Antiretroviral therapy for prevention of tuberculosis in adults with HIV: a systematic review and meta-analysis. PLoS Med. 2012; 9: e1001270.
96. Rodrigues LC, Diwan VD, Wheeler JG,. Protective effect of BCG against tuberculous meningitis and military tuberculosis: a meta analysis. Int. J. Epidemiol. 1993; 22: 1154-1158.
97. Colditz GA, Berkey CS, Mosteller F, et al. The efficacy of bacillus Calmette-Guerin vaccination of newborns and infants in the prevention of tuberculosis: meta-analyses of the published literature. Pediatrics 1995; 96: 29-35.
98. Colditz GA, Brewer TF, Berkey CS, et al. Efficacy of BCG vaccine in the prevention of tuberculosis. JAMA 1994; 271: 698-702.
99. Brewer TF,. Preventing tuberculosis with bacillus Calmette-Guerin vaccine: a meta-analysis of the literature. Clin. Infect. Dis. 2000; 31 (Suppl. 3): S64-67.
100. Abu-Raddad LJ, Sabatelli L, Achterberg JT, et al. Epidemiological benefits of more-effective tuberculosis vaccines, drugs, and diagnostics. Proc. Natl Acad. Sci. U.S.A. 2009; 106: 13980-13985.
101. Kaufmann SH, Hussey G, Lambert P-H,. New vaccines for tuberculosis. Lancet 2010; 375: 2110-2119.
102. Verver S, Warren RM, Beyers N, et al. Rate of reinfection tuberculosis after successful treatment is higher than rate of new tuberculosis. Am. J. Respir. Crit. Care Med. 2005; 171: 1430-1435.
103. Reece ST, Kaufmann S,. Floating between the poles of pathology and protection: can we pin down the granuloma in tuberculosis? Curr. Opin. Microbiol. 2011; 15: 63-70.
104. Gengenbacher M, Kaufmann SHE,. Mycobacterium tuberculosis: success through dormancy. FEMS Microbiol. Rev. 2012; 36: 514-532.
105. Dey B, Jain R, Gupta UD, et al. A booster vaccine expressing a latency-associated antigen augments BCG induced immunity and confers enhanced protection against tuberculosis. PLoS One 2011; 6: e23360.
106. Taylor JL, Wieczorek A, Keyser AR, et al. HspX-mediated protection against tuberculosis depends on its chaperoning of a mycobacterial molecule. Immunol. Cell Biol. 2012; 00: 1-10.
107. Young D, Stark J, Kirschner D,. Systems biology of persistent infection: tuberculosis as a case study. Nat. Rev. Microbiol. 2008; 6: 520-528.
108. Boshoff HIM, Lun DS,. Systems biology approaches to understanding mycobacterial survival mechanisms. Drug Discov. Today Dis. Mech. 2010; 7: e75-e82.
109. Querec TD, Akondy RS, Lee EK, et al. Systems biology approach predicts immunogenicity of the yellow fever vaccine in humans. Nat. Immunol. 2008; 10: 116-125.
110. Ovsyannikova IG, Poland GA,. Vaccinomics: current findings, challenges and novel approaches for vaccine development. AAPS J. 2011; 13: 438-444.